All News | RheumNow

All News

pregnancy.sperm_.jpg

Filgotinib Effects on Semen and Sex Hormones

Save

d Jack Cush, MD

Jul 13, 2023

The oral Janus kinase 1 inhibitor filgotinib is available worldwide, but not in the USA, where the FDA held up its approval for use in RA due to unfinished studies of filgotinib's effects on sperm cells. The results of 2 phase two studies (MANTA and MANTA-RAy) confirm that filgotinib has no measurable impact on semen parameters or sex hormones in men with active IBD or inflammatory rheumatic diseases.

Read Article

antibody (Keep)

Antidrug Antibodies Impair Response to Biologic Drugs

Save

d Jack Cush, MD

Jul 13, 2023

Monitoring for antidrug antibodies with biologic has not been routine in rheumatology but a new study suggests that antidrug antibodies correlate with nonresponse to bDMARDs in rheumatoid arthritis (RA) patients.

Read Article

gout.podagra2.jpg

Pegloticase Plus Methotrexate in Refractory Gout - MIRROR Study 12 mos. Results

Save

d Jack Cush, MD

Jul 12, 2023

The 12-month safety and efficacy of pegloticase + methotrexate (MTX) in the MIRROR trial shows continued efficacy and tophi resolution after 12 months of therapy.

Read Article

early.ra_.2.jpg

Biologics Keep Early RA in Check for at Least One Year

Save

d MedPage Today

Jul 12, 2023

Treatment with at least some biologic drugs significantly reduced 1-year progression of early rheumatoid arthritis (RA) relative to classical small-molecule agents, researchers reported.

Read Article

Covid lung pneumonia corona (keep)

RA Biologics Lower COVID-19 Deaths, but Not Recovery Time

Save

d Jack Cush, MD

Jul 11, 2023

Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care?

Read Article

Biologics Keep Early RA in Check for at Least One Year Treatment with at least some biologic drugs significantly reduced 1-year progression of early rheumatoid arthritis (RA) relative to classical small-molecule agents, researchers reported. https://t.co/FBFX53lZfp https://t.co/l1RapKWlFk

Links:

https://bit.ly/44pmqj9

Dr. John Cush RheumNow ( View Tweet)

Jul 14, 2023

Metanalysis of 8 RCT, 188751 pts assessed mortality risk & FM. Overall, all-cause mortality increased in FM (HR 1.27, 1.04 to 1.51), but not in subgroup Dx by 1990 criteria. Increased SMR for accidents, infxn, suicide & decreased for cancer (0.82) https://t.co/Ujv8KP8FJK https://t.co/lNGUM0wB3O

Links:

https://bit.ly/3XSeWmq

Dr. John Cush RheumNow ( View Tweet)

Jul 14, 2023

ICYMI: RA Disease Activity and Alcohol Use https://t.co/tXuAJ4GRl4 https://t.co/3ieVw8BcIs

Links:

https://bit.ly/43nVLC6

Dr. John Cush RheumNow ( View Tweet)

Jul 13, 2023

35 SLE pts Rx w/ RTX x 3 ys-anti-RTX antibodies found @3 yrs in 64%, higher if previously RTX treated (vs naive). ADA+ had signif lower median RTX levels at 6 mos (P = 0.0018) and increased relapse rates. In vitro showed neutralizing capacity these Abs https://t.co/oV7nHxiS4s https://t.co/p55MvcLDFn

Links:

https://bit.ly/3pMOmOZ

Dr. John Cush RheumNow ( View Tweet)

Jul 13, 2023

Metanalysis 62 RCTs & 16 LTE RCTs looks at neoplasia risk in JAKi, TNFi, MTX, PBO. Total CA rate=1.15/100PYs in RCTs. No diff in all CA between JAKi vs PBO or JAKi vs MTX (IRR 0.77); but JAKi had more CA than TNFi (1.50; 1.16, 1.94) https://t.co/aiJHQ5oPqt https://t.co/8MjJv728sh

Links:

https://bit.ly/3pOmR7I

Dr. John Cush RheumNow ( View Tweet)

Jul 13, 2023

RA Biologics Lower COVID-19 Deaths, but Not Recovery Time Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care? https://t.co/o56m9WumiC. https://t.co/GHe1RprDnk

Links:

https://bit.ly/3OdOeS8

Dr. John Cush RheumNow ( View Tweet)

Jul 13, 2023

Baricitinib Effective in JIA Subsets A phase 3 trial assessed a selective Janus kinase 1/2-inhibitor, baricitinib, in patients with juvenile idiopathic arthritis (JIA), demonstrating it's efficacy and safety compared to placebo. https://t.co/0CMzVCgsG8 https://t.co/NGE1pxsmcb

Links:

https://bit.ly/44K94h4

Dr. John Cush RheumNow ( View Tweet)

Jul 13, 2023

Commercial claims analysis of 21,044 pts w/ simultaneous B/L TKA vs 126,264 matched unilateral TKA. 90 day risk showed B/L TKA had signif more pulmonary embolism (aOR 2.13), CVA (2.21), acute anemia (2.06), transfusion (7.8), 90d readmission (1.35) https://t.co/ZW7fa3fbfC https://t.co/nVqRospVIV

Links:

https://bit.ly/3Ob3xLj

Dr. John Cush RheumNow ( View Tweet)

Jul 12, 2023

JAMA: Prophylaxis for Pneumocystis Pneumonia - indications and Rx - Immuncompromised and Immunodeficient - Pts on Hi Dose Steroids - ANCA–associated vasculitis https://t.co/2VhLxc4VNo https://t.co/cXuY4Manrk

Links:

https://bit.ly/43pboJA

Dr. John Cush RheumNow ( View Tweet)

Jul 12, 2023

ICYMI: ChatGPT - A Boon or Threat to Scientific Publication? https://t.co/nt4m6n27A3 https://t.co/oo88u5X86Z

Links:

https://bit.ly/46Lj7UX

Dr. John Cush RheumNow ( View Tweet)

Jul 12, 2023

GCA and the Risk of Cerebrovascular Ischemic Events Cerebrovascular ischemic events (CIE) can be one of the most severe complications of giant cell arteritis (GCA), but is seen in 4-5% of GCA patients according to a recent French University Hospital. https://t.co/MAjgWg71vK https://t.co/UhMtiWf7gh

Links:

https://bit.ly/3rlawZ3

Dr. John Cush RheumNow ( View Tweet)

Jul 12, 2023

Upadacitinib Outcomes in High Risk RA Patients A safety analysis of six phase III SELECT trials showed that higher-risk RA patients had an increased risk of MACE, malignancy (excluding NMSC) and VTE regardless of being treated with either UPA or ADA. https://t.co/7JXntIV09K https://t.co/CthPcu2Ohs

Links:

https://bit.ly/46Nl7vW

Dr. John Cush RheumNow ( View Tweet)

Jul 12, 2023

A double-blind, sham-controlled RCT of auricular vagus nerve stimulation (VNS) showed NO meaningful improvement in 101 RA completers. @week 12, ACR20 was 25% for VNS vs 27% for sham (NS). Also NS was change in DAS28-CRP (–0.95 vs –0.66)(p 0.06) https://t.co/NubTu8mGq4 https://t.co/OQSIpHgLyn

Links:

https://bit.ly/43oztjD

Dr. John Cush RheumNow ( View Tweet)

Jul 11, 2023

ICYMI: Hydroxychloroquine Dose and Risk for Incident Retinopathy A cohort study in Annals of Internal Medicine shows that higher hydroxychloroquine doses was associated with progressively greater risk for incident retinopathy. https://t.co/SLgUKQKbFs https://t.co/xCc2D5Hx8S

Links:

https://bit.ly/44hBcbV

Dr. John Cush RheumNow ( View Tweet)

Jul 11, 2023

ICYMI: 25 Great Women in Rheumatology https://t.co/ghCAUBMMja https://t.co/cr2xI2VrgE

Links:

https://bit.ly/46Kewm3

Dr. John Cush RheumNow ( View Tweet)

Jul 11, 2023

×